TFF Pharmaceuticals announced that Glenn Mattes will step down as CEO and Member of the Board of Directors. Dr. Harlan Weisman, Vice Chairman of the Board, has been appointed Interim CEO, effective December 5. Harlan F. Weisman, M.D. has more than 30 years of experience as a senior healthcare executive responsible for the discovery, development, regulatory approval and launch of pharmaceutical, biopharmaceutical, medical device and diagnostic products. He is currently Managing Director of And-One Consulting, LLC, advising medical product companies, investment firms, and government and non-government healthcare organizations in formulating and implementing strategies for driving innovation in healthcare products and services.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TFFP:
- TFF Pharmaceuticals Announces Leadership Transition
- TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering
- TFF Pharmaceuticals Prices $10.675 Million Offering of Common Stock and Warrants
- TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
- TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update